BGB-A317-A3055-101

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors.

Open at Paris since : 13/03/2024
Target : Adult
Phase : Phase I/II

Trial description

To assess the safety and tolerability of BGB-A3055 alone and in combination with tislelizumab in patients with advanced or metastatic solid tumors.

Url of the trial

Main investigator

CHRISTOPHE LE TOURNEAU

Professeur - Médecin

Contact